Pfizer Inc.

• Fund in Focus: George Putnam Fund of Boston

  By Staff Writer  |  August 26, 2005

  Jeanne L. Mockard, lead manager since April 2000 S&P Rank: 3 Stars Venerable Fund Sticks To Its Knitting

• Richard Cervone of Putnam Tax-Smart Equity Fund

  By Staff Writer  |  February 15, 2005

  S&P Rank: 5 Stars Tax-Aware Fund Seeks Good Fundamentals First

• Mark Mulholland of Matthew 25 Fund

  By Staff Writer  |  December 23, 2004

  S&P Rank: 5 Stars Keeping His Investment Lamp Trimmed

• John C. Thompson of Thompson Plumb Growth Fund

  By Staff Writer  |  August 27, 2004

  S&P Rank: 5 Stars Growth, By Any Other Name

• Fund in Focus: Smith Barney Fundamental Value Fund

  By Staff Writer  |  July 19, 2004

  July 16, 2004 -- The Smith Barney Fundamental Value/A (SHFVX) began buying large pharmaceuticals companies late last year. At that time, their stocks were trading...

• Fund in Focus: Evergreen Strategic Growth Fund

  By Staff Writer  |  May 5, 2004

  Jay Zelko, co-manager since April 2000 S&P Rank: Not Ranked. Best Expectations

• Durus Settles, Pays Esperion $32 Million

  By Staff Writer  |  January 26, 2004

  ANN ARBOR, Mich. (HedgeWorld.com)--Esperion Therapeutics Inc., settled its civil lawsuit against Durus Life Sciences Master Fund Ltd., three weeks after Esperion agreed to be acquired...

• Liu-Er Chen of Evergreen Health Care Fund

  By Staff Writer  |  August 25, 2003

  S&P Rank: 4 Stars Aug. 14, 2003 On the Cusp of a New Drug Boom Quick Take: Drug and biotech stocks suffered in 2002, hurt by poor earnings,...

• Evan McCulloch of Franklin Biotechnology Discovery

  By Staff Writer  |  February 10, 2003

  S&P Rank: 3 Stars Strong Dose of Biotech

• Michael Yellen of AIM Global Health Care Fund

  By Staff Writer  |  January 31, 2003

  S&P Rank: 4 Stars Good Prognoses for Drug Stocks